Cytek Biosciences (CTKB) Stock Price, News & Analysis

Company Overview

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Key Stats

• Today's Range: $4.95 to $5.23
• 50-Day Range: $4.69 to $5.74
• 52-Week Range: $3.80 to $9.87
• Volume: 824,291 shs
• Average Volume: 669,180 shs
• Market Capitalization: $672.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Moderate Buy

Cytek Biosciences Stock Analysis - MarketRank™

Cytek Biosciences scored higher than 37% of companies evaluated by MarketBeat, and ranked 746th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cytek Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Cytek Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cytek Biosciences are expected to grow in the coming year, from ($0.11) to $0.03 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cytek Biosciences is -36.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cytek Biosciences is -36.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cytek Biosciences has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.74% of the float of Cytek Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Cytek Biosciences has a short interest ratio ("days to cover") of 7.4.

Change versus previous month

Short interest in Cytek Biosciences has recently increased by 3.95%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cytek Biosciences does not currently pay a dividend.

Dividend Growth

Cytek Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.74% of the float of Cytek Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Cytek Biosciences has a short interest ratio ("days to cover") of 7.4.

Change versus previous month

Short interest in Cytek Biosciences has recently increased by 3.95%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Cytek Biosciences this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for CTKB on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cytek Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.60% of the stock of Cytek Biosciences is held by insiders.

Percentage Held by Institutions

69.46% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CTKB Stock Analysis - Frequently Asked Questions

How have CTKB shares performed this year?

Cytek Biosciences' stock was trading at $9.12 on January 1st, 2024. Since then, CTKB stock has decreased by 44.0% and is now trading at $5.11.
View the best growth stocks for 2024 here.

How were Cytek Biosciences' earnings last quarter?

Cytek Biosciences, Inc. (NASDAQ:CTKB) released its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.05. The business earned $46.62 million during the quarter, compared to analyst estimates of $49.02 million. Cytek Biosciences had a negative trailing twelve-month return on equity of 3.75% and a negative net margin of 8.88%.

When did Cytek Biosciences IPO?

Cytek Biosciences (CTKB) raised $248 million in an IPO on Friday, July 23rd 2021. The company issued 14,564,635 shares at $16.00-$18.00 per share.

Who are Cytek Biosciences' major shareholders?

Top institutional investors of Cytek Biosciences include Principal Financial Group Inc. (0.38%), State of Alaska Department of Revenue (0.05%), Louisiana State Employees Retirement System (0.04%) and Everence Capital Management Inc. (0.01%). Insiders that own company stock include Ming Yan, Wenbin Jiang, Patrik Jeanmonod, Jack Ball and Ra Capital Management, LP.
View institutional ownership trends.

How do I buy shares of Cytek Biosciences?

Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Cytek Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytek Biosciences investors own include American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY) and Humana (HUM).

Company Calendar

• Last Earnings: 8/06/2024
• Today: 11/02/2024
• Next Earnings (Confirmed): 11/05/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:CTKB
• CUSIP: N/A
• CIK: 1831915
• Web: www.cytekdev.com
• Phone: 877-922-9835
• Fax: N/A
• Employees: 500
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.50
• High Stock Price Target: $10.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +66.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-12,150,000.00
• Net Margins: -8.88%
• Pretax Margin: -8.22%
• Return on Equity: -3.75%
• Return on Assets: -3.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.33
• Quick Ratio: 6.38

Sales & Book Value

• Annual Sales: $193.01 million
• Price / Sales: 3.48
• Cash Flow: $0.03 per share
• Price / Cash Flow: 194.26
• Book Value: $2.90 per share
• Price / Book: 1.76

Miscellaneous

• Outstanding Shares: 131,510,000
• Free Float: 118,881,000
• Market Cap: $672.02 million
• Optionable: Optionable
• Beta: 1.30